Lenvatinib - Eisai Co Ltd

Drug Profile

Lenvatinib - Eisai Co Ltd

Alternative Names: E-7080; ER-203492-00; Kisplyx; Lenvatinib mesylate; LENVIMA; Lenvima; MK-7902

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; Merck & Co; MSD KK; National Cancer Center (Tokyo); National University Hospital (Singapore); Ono Pharmaceutical; SFJ Pharmaceuticals
  • Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Phenyl ethers; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Liver cancer; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Renal cell carcinoma; Thyroid cancer
  • Phase III Endometrial cancer
  • Phase II Biliary cancer; Gastric cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Thymoma
  • Phase I/II Breast cancer; Solid tumours
  • Phase I Ovarian cancer
  • Discontinued Cancer; Glioma; Lymphoma

Most Recent Events

  • 13 Nov 2018 Phase-III clinical trials in Endometrial cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Ireland, Taiwan, Russia, South Korea, Japan, Israel, France (PO) (NCT03517449) prior to November 2018
  • 12 Nov 2018 Launched for Liver cancer (First-line therapy, Inoperable/Unresectable, Monotherapy) in China (PO)
  • 22 Oct 2018 Merck and Eisai plans the phase III LEAP-002 trail in combination with pembrolizumab for Hepatocellular carcinoma (First-line therapy, Late-stage disease, Second line therapy or greater) in December 2019 (PO) (NCT03713593)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top